Mantle Cell Lymphoma International Prognostic Index (MIPI)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-MCL-MIPI |
|---|---|
| Type | Biomarker |
| Aliases | MIPI scoreMIPI — прогностичний індекс для MCL |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | composite_score |
|---|---|
| Measurement | Method4 variables: age, ECOG, LDH, WBC; biological MIPI adds Ki67 Unitslow (≤5.7) / int (5.7-6.2) / high (>6.2) |
| Related biomarkers | None declared |
Notes
Stratifies into low (5y OS ~80%), int (~50%), high (~30%). Biological MIPI (MIPI-b) incorporates Ki67 % — better discrimination especially in fit patients. Informs prognosis counsel; less directly drives 1L regimen choice than fitness assessment + TP53 status.
Used By
Indications
IND-MCL-1L-BTKI-R- IND-MCL-1L-BTKI-RIND-MCL-1L-INTENSIVE- IND-MCL-1L-INTENSIVEIND-MCL-2L-ACALABRUTINIB- IND-MCL-2L-ACALABRUTINIB
Questionnaires
QUEST-MCL-1L-STUB- Mantle Cell Lymphoma — first line